March 13, 2020 / 10:48 AM / 25 days ago

BRIEF-Telix Pharmaceuticals Updates On Co's Risk Management Assessment Of Impact Of Covid-19

March 13 (Reuters) - Telix Pharmaceuticals Ltd:

* UPDATES ON CO’S RISK MANAGEMENT ASSESSMENT OF NOVEL CORONAVIRUS PANDEMIC

* HAS SUFFICIENT CASH RESERVES & CONTINGENCY PLANS FOR SIGNIFICANT DELAYS IN CLINICAL, REGULATORY AND COMMERCIAL ACTIVITY

* RISKS INCLUDE INTERRUPTIONS TO DRUG PRODUCT MANUFACTURING, LOGISTICS INTERRUPTIONS DUE TO CANCELLED OR RE-ROUTED FLIGHTS

* ACTIVELY PLANNING FOR DISRUPTIONS THAT COULD POTENTIALLY LEAD TO SHORT-TERM DELAYS IN ACCOMPLISHING KEY BUSINESS OBJECTIVES

* HAS CASH RUNWAY UNTIL MID-2021, CAN BE EXTENDED TO END-2021 WITHOUT MAJOR HIT

* RISKS ALSO INCLUDE DELAYS IN REGULATORY REVIEWS DUE TO GOVERNMENT-MANDATED ISOLATION & TRAVEL CANCELLATION POLICIES

* HAS SUFFICIENT CASH RESERVES & CONTINGENCY PLANS FOR SIGNIFICANT DELAYS IN CLINICAL, REGULATORY AND COMMERCIAL ACTIVITY

* RISKS INCLUDE INTERRUPTIONS TO DRUG PRODUCT MANUFACTURING, LOGISTICS INTERRUPTIONS DUE TO CANCELLED OR RE-ROUTED FLIGHTS

* ACTIVELY PLANNING FOR DISRUPTIONS THAT COULD POTENTIALLY LEAD TO SHORT-TERM DELAYS IN ACCOMPLISHING KEY BUSINESS OBJECTIVES

* HAS CASH RUNWAY UNTIL MID-2021, CAN BE EXTENDED TO END-2021 WITHOUT MAJOR HIT

* RISKS ALSO INCLUDE DELAYS IN REGULATORY REVIEWS DUE TO GOVERNMENT-MANDATED ISOLATION & TRAVEL CANCELLATION POLICIES

* UPDATES ON CO’S RISK MANAGEMENT ASSESSMENT OF NOVEL CORONAVIRUS PANDEMIC Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below